Literature DB >> 25199199

Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.

Jillian Maclean1, Rodney H Breau1, Nicola Scheida1, Shawn Malone1.   

Abstract

Renal cell carcinoma (RCC) is generally poorly responsive to conventional radiation doses, and patients with inoperable local recurrence have limited therapeutic options. Stereotactic body radiotherapy (SBRT) is an increasingly available technology that allows delivery of a radiation schedule providing doses far more biologically effective against cancer cells than conventional radiotherapy. We present a case where durable disease control was achieved using SBRT in a patient with inoperable locally recurrent RCC who presented 18 years from original nephrectomy. The patient remains asymptomatic with no evidence of active disease 30 months following SBRT. This case highlights the need to reconsider the role of therapies with continuing advances in technology. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25199199      PMCID: PMC4158231          DOI: 10.1136/bcr-2014-206015

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  An overview of hypofractionation and introduction to this issue of seminars in radiation oncology.

Authors:  Robert D Timmerman
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

Review 2.  CyberKnife for inoperable renal tumors: Canadian pioneering experience.

Authors:  Vimoj J Nair; Janos Szanto; Eric Vandervoort; Ilias Cagiannos; Rodney Breau; Colin Malone; Leonard Avruch; Jason Pantarotto; Shawn Malone
Journal:  Can J Urol       Date:  2013-10       Impact factor: 1.344

Review 3.  A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma.

Authors:  Shankar Siva; Daniel Pham; Suki Gill; Niall M Corcoran; Farshad Foroudi
Journal:  BJU Int       Date:  2012-10-29       Impact factor: 5.588

4.  Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma.

Authors:  Ehsan H Balagamwala; Lilyana Angelov; Shlomo A Koyfman; John H Suh; Chandana A Reddy; Toufik Djemil; Grant K Hunter; Ping Xia; Samuel T Chao
Journal:  J Neurosurg Spine       Date:  2012-09-28

5.  Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control.

Authors:  Niraj Mehta; Christopher R King; Nzhde Agazaryan; Michael Steinberg; Amanda Hua; Percy Lee
Journal:  Pract Radiat Oncol       Date:  2011-12-03

6.  Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases.

Authors:  Hideyuki Kano; Aditya Iyer; Douglas Kondziolka; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Neurosurgery       Date:  2011-12       Impact factor: 4.654

7.  Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.

Authors:  S Ning; K Trisler; B W Wessels; S J Knox
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

8.  Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.

Authors:  Jason P Sheehan; Ming-Hsi Sun; Douglas Kondziolka; John Flickinger; L Dade Lunsford
Journal:  J Neurosurg       Date:  2003-02       Impact factor: 5.115

9.  Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.

Authors:  Vitaly Margulis; Michelle McDonald; Pheroze Tamboli; David A Swanson; Christopher G Wood
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

10.  Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer.

Authors:  J Martin Brown; David J Brenner; David J Carlson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.